File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of JTT-501 on net hepatic glucose balance and peripheral glucose uptake in alloxan-induced diabetic dogs

TitleEffect of JTT-501 on net hepatic glucose balance and peripheral glucose uptake in alloxan-induced diabetic dogs
Authors
Issue Date2000
Citation
Metabolism: Clinical and Experimental, 2000, v. 49, n. 7, p. 862-867 How to Cite?
AbstractJTT-501, a new insulin sensitizer, improves peripheral glucose uptake in insulin-resistant animals such as KK-Ay mice and Zucker fatty rats. However, the effect of JTT-501 on hepatic glucose metabolism has not been addressed. To investigate this effect, experiments were performed on 6 alloxan-diabetic dogs. Three experiments were conducted for each dog: the treatment experiment, which followed a 10-day oral treatment with JTT-501 30 mg · kg- 1 · d-1, and 2 control experiments 2 weeks before and 2 weeks after the treatment experiment. A hyperinsulinemic-hyperglycemic clamp was performed with the tracer dilution method (intraportal insulin infusion rate, 18 pmol · kg-1 · min-1). Arterial hyperglycemia (~10 mmol/L) was maintained by adjusting the peripheral glucose infusion rate. After a 45-minute basal period (period I), portal glucose infusion (22.2 μmol · kg-1 min-1) was administered for 120 minutes (period II). This was followed by a 90-minutes recovery period (period III). JTT-501 increased insulin-stimulated glucose utilization (P < .05) and enhanced insulin-mediated suppression of glucose production (P < .05) in periods I and III. Net hepatic glucose balance (NHGB) determined by the arterial-venous (A-V) difference method was increased by JTT-501 in period II (P < .01). We conclude that JTT-501 enhances both hepatic and peripheral insulin sensitivity and therefore may have important therapeutic effects in type 2 diabetes. Copyright (C) 2000 by W.B. Saunders Company.
Persistent Identifierhttp://hdl.handle.net/10722/222625
ISSN
2015 Impact Factor: 4.375
2015 SCImago Journal Rankings: 1.978

 

DC FieldValueLanguage
dc.contributor.authorNiwa, Masataka-
dc.contributor.authorRashid, Shirya-
dc.contributor.authorShum, Kathy-
dc.contributor.authorMathoo, Julian M R-
dc.contributor.authorChan, Owen-
dc.contributor.authorTchipashvili, Vaja-
dc.contributor.authorKawamori, Ryuzo-
dc.contributor.authorVranic, Mladen-
dc.contributor.authorGiacca, Adria-
dc.date.accessioned2016-01-19T03:36:36Z-
dc.date.available2016-01-19T03:36:36Z-
dc.date.issued2000-
dc.identifier.citationMetabolism: Clinical and Experimental, 2000, v. 49, n. 7, p. 862-867-
dc.identifier.issn0026-0495-
dc.identifier.urihttp://hdl.handle.net/10722/222625-
dc.description.abstractJTT-501, a new insulin sensitizer, improves peripheral glucose uptake in insulin-resistant animals such as KK-Ay mice and Zucker fatty rats. However, the effect of JTT-501 on hepatic glucose metabolism has not been addressed. To investigate this effect, experiments were performed on 6 alloxan-diabetic dogs. Three experiments were conducted for each dog: the treatment experiment, which followed a 10-day oral treatment with JTT-501 30 mg · kg- 1 · d-1, and 2 control experiments 2 weeks before and 2 weeks after the treatment experiment. A hyperinsulinemic-hyperglycemic clamp was performed with the tracer dilution method (intraportal insulin infusion rate, 18 pmol · kg-1 · min-1). Arterial hyperglycemia (~10 mmol/L) was maintained by adjusting the peripheral glucose infusion rate. After a 45-minute basal period (period I), portal glucose infusion (22.2 μmol · kg-1 min-1) was administered for 120 minutes (period II). This was followed by a 90-minutes recovery period (period III). JTT-501 increased insulin-stimulated glucose utilization (P < .05) and enhanced insulin-mediated suppression of glucose production (P < .05) in periods I and III. Net hepatic glucose balance (NHGB) determined by the arterial-venous (A-V) difference method was increased by JTT-501 in period II (P < .01). We conclude that JTT-501 enhances both hepatic and peripheral insulin sensitivity and therefore may have important therapeutic effects in type 2 diabetes. Copyright (C) 2000 by W.B. Saunders Company.-
dc.languageeng-
dc.relation.ispartofMetabolism: Clinical and Experimental-
dc.titleEffect of JTT-501 on net hepatic glucose balance and peripheral glucose uptake in alloxan-induced diabetic dogs-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1053/meta.2000.6752-
dc.identifier.pmid10909996-
dc.identifier.scopuseid_2-s2.0-0034235123-
dc.identifier.volume49-
dc.identifier.issue7-
dc.identifier.spage862-
dc.identifier.epage867-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats